SUPRIYA · Supriya Lifescience Limited · Financials
Volume · Nov 13
10.81K
Avg daily vol (3M)
22.93K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
8.28B
+18.9%
FY2026
Net Income
2.09B
+11.3%
FY2026
Operating Cash Flow
1.86B
+12.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| INR | 8.79B | 8.28B | 6.96B | 5.7B | 4.61B | 5.3B |
| INR | 337.18M | 284.09M | 204.44M | 158.11M | 118.15M | 101.18M |
| INR | 17.93M | 18.89M | 16.86M | 21.1M | 30.84M | 41.98M |
| INR | 2.38B | 2.75B | 2.48B | 1.66B | 1.23B | 2.07B |
| INR | 604.22M | 656.59M | 605.23M | 465.76M | 336.3M | 554.35M |
| INR | 1.77B | 2.09B | 1.88B | 1.19B | 898.59M | 1.52B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 285.36M in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.